Letrozolo Pensa Pharma

Letrozole, the active ingredient in Letrozolo Pensa Pharma, is a aromatase inhibitor presented as a tablet for oral use. It treats hormone receptor‑positive breast cancer in postmenopausal women by lowering estrogen levels that can fuel tumor growth.

GNH USA supplies Letrozolo Pensa Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Letrozolo Pensa Pharma is an aromatase inhibitor indicated for hormone‑driven breast cancer conditions.

- Hormone receptor‑positive breast cancer in postmenopausal women: reduces tumor progression by limiting estrogen synthesis. - Adjuvant therapy after surgery: lowers the risk of disease recurrence. - Metastatic breast cancer: improves overall survival in advanced disease settings.

Adverse reactions may occur with Letrozolo Pensa Pharma. Patients should be aware of both frequent and less common events.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint pain: aching or stiffness in joints. - Nausea: mild to moderate upset stomach. - Fatigue: persistent tiredness not relieved by rest.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated enzymes, hepatic failure. - Bone fracture: increased risk due to reduced bone mineral density. - Deep vein thrombosis: swelling, pain, and redness in limbs indicating clot formation.

Before initiating Letrozolo Pensa Pharma, clinicians should consider several safety measures.

- Bone health monitoring: assess bone mineral density periodically. - Liver function assessment: perform baseline and periodic liver enzyme tests. - Cardiovascular risk evaluation: review history of thrombosis or heart disease. - Pregnancy contraindication: avoid use in pregnant or breastfeeding women (Category X). - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Letrozolo Pensa Pharma may interact with other medicines; some require avoidance while others need careful monitoring.

Major Interactions (Avoid): - Estrogen replacement therapy: antagonizes the drug’s effect. - Tamoxifen: combined use may reduce efficacy of both agents. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase letrozole plasma levels.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Statins: potential for increased muscle toxicity, observe symptoms. - Carbamazepine: enzyme inducer that may lower letrozole concentrations.